Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients. (Q51774046)
Jump to navigation
Jump to search
scientific article published in March 2009
- Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients. |
scientific article published in March 2009 |
|
Statements
Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients. (English)
1 reference
Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients (English)
0 references
Zoraida Verde
1 reference
Catalina Santiago
1 reference
Beatriz Valle
1 reference
Fernando Bandrés
1 reference
Elpidio Calvo
1 reference
Jonatan R Ruiz
1 reference
Alejandro Lucía
1 reference
Félix Gómez Gallego
1 reference
1 March 2009
1 reference
2009
0 references
101
1 reference
3
1 reference
03
0 references
591-593
1 reference